-
Mashup Score: 1Wearable Medical Devices Market is anticipated to reach a valuation of US$ 73.48 Billion by 2032 - 1 year(s) ago
The global wearable medical devices market is estimated to be worth US$ 27.29 billion by 2022, growing at a moderate CAGR of 28.1% from 2022 to 2032. The market for wearable medical devices is expected to be worth around US$ 73.48 billion by 2032.With 5G and AI, the most likely diagnosis and trea…
Source: PharmiWeb.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1
Open, scalable, end-to-end solution to improve diagnostic quality and efficiencySANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated end-to-end solution for digital pathology that brings together best-in-class products from Agilent, Visiop…
Source: PharmiWeb.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @pharminews: Agilent Announces End-to-End Digital Pathology Workflow Solution at USCAP 2023 https://t.co/lafxHbkcTE #USCAP2023 #Digital…
-
-
Mashup Score: 0How eCOA Improves Patient Experience and Data Quality - 1 year(s) ago
With the rising demand for improving patient safety in clinical trials, the adoption of patient-centric solutions is considered the best route to enhance data accuracy and experience automated workflows. This is where eCOA comes into play. In this blog post, we will find out how electronic clinic…
Source: PharmiWeb.comCategories: Future of Medicine, Latest HeadlinesTweet-
How eCOA Improves Patient Experience and Data Quality https://t.co/9BvrjIT6wA https://t.co/nHf5MQExqk
-
-
Mashup Score: 4NICE Recommends RINVOQ®▼(upadacitinib) As A Treatment Option For Active Ankylosing Spondylitis (AS) In Adults - 2 year(s) ago
NICE Recommends RINVOQ®▼(upadacitinib) As A Treatment Option For Active Ankylosing Spondylitis (AS) In Adults Publication of a positive Final Appraisal Document (FAD) means RINVOQ®▼(upadacitinib) will be available in England and Wales as a treatment option for active ankylosing spond…
Source: PharmiWeb.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
NICE has approved upadacitinib (Rinvoq) for availability in England & Wales for use in adults w/ active ankylosing spondylitis not controlled with conventional therapy, only after TNF inhibitors are tried or not suitable https://t.co/MV47NPb2EF https://t.co/9Le2Sj5aNI
-
-
Mashup Score: 0North America Digital Therapeutic (DTx) Market is growing with a CAGR of 23.4% and is expected to r - 2 year(s) ago
DBMR has recently updated the North America Digital Therapeutic (DTx) Market research report gives the knowledge of all the above factors with transparent, wide-ranging, and supreme quality market studies. The report focuses on many aspects related to industry and market. Some of the marketing st…
Source: PharmiWeb.comCategories: Future of Medicine, Latest HeadlinesTweet-
North America Digital Therapeutic #DTx Market is growing with a CAGR of 23.4% and is expected to r https://t.co/GX70mg6Iq8 https://t.co/V3p5NJLd1S
-
-
Mashup Score: 2NICE recommends AbbVie’s RINVOQ® ▼ (upadacitinib) For Use in Adults with Active Psoriatic Arthritis - 2 year(s) ago
NICE recommends AbbVie’s RINVOQ® ▼ (upadacitinib) For Use in Adults with Active Psoriatic Arthritis This decision means that upadacitinib will be available in England and Wales for eligible patients with previously treated active psoriatic arthritis (PsA).1Across pivotal clinical t…
Source: PharmiWeb.comCategories: Latest Headlines, RheumatologyTweet-
NICE (UK) has recommended upadacitinib for use in active Psoriatic Arthritis, 15 mg qd +/- MTX, in pts not responding to DMARDS. UPA can now be used in England Wales and Scotland https://t.co/JFxMrgjrUe
-
-
Mashup Score: 2Voluntis and AliveCor Partner to Advance Management of Atrial Fibrillation for Patients with Cancer - 2 year(s) ago
Voluntis and AliveCor Partner to Advance Management of Atrial Fibrillation for Patients with CancerCambridge, Massachusetts and Mountain View, California, January 6, 2022 – Voluntis, an Aptar Pharma company and leader in digital therapeutics, today announced that it has entered into a partnership…
Source: PharmiWeb.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @pharminews: Voluntis and AliveCor Partner to Advance Management of Atrial Fibrillation for Patients with Cancer https://t.co/RsrBybHH4p…
-
-
Mashup Score: 0Crises can’t be dealt with until they are recognised - 2 year(s) ago
Crises can’t be dealt with until they are recognisedBy Robert Hewitt, MB BS, PhD, Biosample HubIf a crisis is recognised, it can be a powerful accelerator of change. But do we always spot a crisis when we see it? Often there needs to be a key event (or series of events) to highlight the sit…
Source: PharmiWeb.comCategories: Future of Medicine, Latest HeadlinesTweet-
Crises can’t be dealt with until they are recognised #NBTintheNews via @pharmiweb_com https://t.co/xGT52hKuSI
-
-
Mashup Score: 0European Commission approves Benlysta for adult patients with active lupus nephritis - 3 year(s) ago
GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous and subcutaneous BENLYSTA (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN) in Europe, in …
Source: PharmiWeb.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
ICYMI: Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis https://t.co/Twbe1ClT5w
-
-
Mashup Score: 10European Commission approves Benlysta for adult patients with active lupus nephritis - 3 year(s) ago
GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous and subcutaneous BENLYSTA (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN) in Europe, in …
Source: PharmiWeb.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Top May Tweet: Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis https://t.co/Twbe1ClT5w
-
Wearable #MedicalDevice Market is anticipated to reach a valuation of US$ 73.48 Billion by 2032 https://t.co/wEcSsaNclE #MedTech #AI #AppleWatch #healthcare #HealthTech #HealthIT #HIMSS23 #wearables #RPM #5G #WearableTech https://t.co/OgecDMpJVq